​

KALA BIO Stock (NASDAQ:KALA)

ForecastOwnershipFinancialsChart
KALA BIO by TradingView

Previous Close

$17.00

52W Range

$2.92 - $18.89

50D Avg

$8.74

200D Avg

$6.56

Market Cap

$130.73M

Avg Vol (3M)

$188.51K

Beta

-1.82

Div Yield

-

KALA Company Profile

Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

38

IPO Date

Jul 20, 2017

Website

KALA Performance

KALA Financial Summary

Dec 24Dec 23Dec 22
Revenue--$3.89M
Operating Income$-40.98M$-39.15M$-81.36M
Net Income$-38.51M$-42.20M$-223.00K
EBITDA$-40.98M$-36.08M$-36.70M
Basic EPS$-1.01$-17.35$-0.15
Diluted EPS$-1.01$-17.35$-0.15

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 22Aug 12, 22 | 8:00 AM
Q1 22May 16, 22 | 8:00 AM
Q4 21Mar 29, 22 | 8:00 AM

Peer Comparison

TickerCompany
HOTHHoth Therapeutics, Inc.
SHPHShuttle Pharmaceuticals Holdings, Inc.
IRWDIronwood Pharmaceuticals, Inc.
LFCRLifecore Biomedical, Inc.
CTMXCytomX Therapeutics, Inc.
PTPIPetros Pharmaceuticals, Inc.
KPTIKaryopharm Therapeutics Inc.
ARDXArdelyx, Inc.
PALIPalisade Bio, Inc.